Critical Role of LSEC in Post-Hepatectomy Liver Regeneration and Failure
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Engineered Liver-On-A-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: a Review
micromachines Review Engineered Liver-On-A-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review 1, 1, 2, 1, 1 Jiu Deng y, Wenbo Wei y, Zongzheng Chen y , Bingcheng Lin *, Weijie Zhao , Yong Luo 1 and Xiuli Zhang 3,* 1 State Key Laboratory of Fine Chemicals, Department of Chemical Engineering, Dalian University of Technology, Dalian 116024, China; [email protected] (J.D.); [email protected] (W.W.); [email protected] (W.Z.); [email protected] (Y.L.) 2 Integrated Chinese and Western Medicine Postdoctoral research station, Jinan University, Guangzhou 510632, China; [email protected] 3 College of Pharmaceutical Science, Soochow University, Suzhou 215123, China * Correspondence: [email protected] (B.L.); [email protected] (X.Z.); Tel.: +86-0411-8437-9065 (B.L.); +86-155-0425-7723 (X.Z.) These authors have equally contribution to this work. y Received: 17 September 2019; Accepted: 3 October 2019; Published: 7 October 2019 Abstract: Hepatology and drug development for liver diseases require in vitro liver models. Typical models include 2D planar primary hepatocytes, hepatocyte spheroids, hepatocyte organoids, and liver-on-a-chip. Liver-on-a-chip has emerged as the mainstream model for drug development because it recapitulates the liver microenvironment and has good assay robustness such as reproducibility. Liver-on-a-chip with human primary cells can potentially correlate clinical testing. Liver-on-a-chip can not only predict drug hepatotoxicity and drug metabolism, but also connect other artificial organs on the chip for a human-on-a-chip, which can reflect the overall effect of a drug. -
About Liver Resection
ABOUT LIVER RESECTION Surgical removal of part of the liver A guide for patients and relatives This booklet has been written to provide information about the operation called a liver resection. This is a major operation and involves removal of a part of the liver. Information about the benefits and risks will help you make an informed decision about the operation. It is important to remember that each person is different. This booklet cannot replace the professional advice and expertise of a doctor who is familiar with your condition. If you have questions that this booklet does not cover, please discuss them with your surgeon or cancer nurse specialist. page 2 What is the liver? The liver is a large organ which lies on the right side of the upper abdomen, under the rib cage. It has many functions related to body metabolism (chemical processes within the body) and is very important to health. One of its functions is to produce yellow-green fluid called bile. Bile flows down a tube called the bile duct to the intestine, where it mixes with food and helps digestion. The gall bladder is a small sac attached to the side of the bile duct. The gall bladder stores excess bile and pushes it down the bile duct in to the intestine, ready for when it is needed for digestion. The liver has right and left lobes (sections). An artery (hepatic artery) and a vein (portal vein) carry blood to the liver. Blood from the liver flows through the hepatic veins back to the heart. -
Liver Resections Combined with Closure of Loop Ileostomies: a Retrospective Analysis
Hindawi Publishing Corporation HPB Surgery Volume 2008, Article ID 501397, 5 pages doi:10.1155/2008/501397 Research Article Liver Resections Combined with Closure of Loop Ileostomies: A Retrospective Analysis Jeffrey T. Lordan, Angela T. Riga, and Nariman D. Karanjia Regional Hepato-Pancreatico-Biliary Unit for Surrey and Sussex, The Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK Correspondence should be addressed to Jeffrey T. Lordan, dr [email protected] Received 6 August 2008; Accepted 30 October 2008 Recommended by Olivier Farges Background. The management of patients with colorectal liver metastases and loop ileostomies remains controversial. This study was performed to assess the outcome of combined liver resection and loop ileostomy closure. Methods. Analysis of prospectively collected perioperative data, including morbidity and mortality, of 283 consecutive hepatectomies for colorectal liver metastases was undertaken. Consecutive liver resections were performed from 1996 to 2006 in one centre by a single surgeon (NDK). Fourteen of these patients had combined liver resection and ileostomy closure. Case-matched analysis was undertaken. Results.Six(2.2%) patients died in the hepatectomy only group and none died in the combined group. There was no difference in operative blood loss between the two groups (0.09). Perioperative morbidity was 36% in the combined group and 23% in the hepatectomy alone group (P = 0.33). Mean hospital stay was 14 days in the combined group and 11 days in the hepatectomy only group (P = 0.046). Case-matched analysis showed a significant increase in hospital stay (P = 0.03) and complications (P = 0.049) in the combined group. -
Nomina Histologica Veterinaria, First Edition
NOMINA HISTOLOGICA VETERINARIA Submitted by the International Committee on Veterinary Histological Nomenclature (ICVHN) to the World Association of Veterinary Anatomists Published on the website of the World Association of Veterinary Anatomists www.wava-amav.org 2017 CONTENTS Introduction i Principles of term construction in N.H.V. iii Cytologia – Cytology 1 Textus epithelialis – Epithelial tissue 10 Textus connectivus – Connective tissue 13 Sanguis et Lympha – Blood and Lymph 17 Textus muscularis – Muscle tissue 19 Textus nervosus – Nerve tissue 20 Splanchnologia – Viscera 23 Systema digestorium – Digestive system 24 Systema respiratorium – Respiratory system 32 Systema urinarium – Urinary system 35 Organa genitalia masculina – Male genital system 38 Organa genitalia feminina – Female genital system 42 Systema endocrinum – Endocrine system 45 Systema cardiovasculare et lymphaticum [Angiologia] – Cardiovascular and lymphatic system 47 Systema nervosum – Nervous system 52 Receptores sensorii et Organa sensuum – Sensory receptors and Sense organs 58 Integumentum – Integument 64 INTRODUCTION The preparations leading to the publication of the present first edition of the Nomina Histologica Veterinaria has a long history spanning more than 50 years. Under the auspices of the World Association of Veterinary Anatomists (W.A.V.A.), the International Committee on Veterinary Anatomical Nomenclature (I.C.V.A.N.) appointed in Giessen, 1965, a Subcommittee on Histology and Embryology which started a working relation with the Subcommittee on Histology of the former International Anatomical Nomenclature Committee. In Mexico City, 1971, this Subcommittee presented a document entitled Nomina Histologica Veterinaria: A Working Draft as a basis for the continued work of the newly-appointed Subcommittee on Histological Nomenclature. This resulted in the editing of the Nomina Histologica Veterinaria: A Working Draft II (Toulouse, 1974), followed by preparations for publication of a Nomina Histologica Veterinaria. -
793 H. Chen (Ed.), Illustrative Handbook of General Surgery, DOI
Index A anesthetization , 763 Abdominoperineal resection incision , 763, 764 (APR) informed consent , 762 anesthesia , 432–433 packing abscess cavity , indications , 430–431 764, 765 patient positioning , 432 potential risks, disclosure post-operative care , 446 of , 762 pre-operative imaging and protective equipment , 762 procedures , 431–432 skin preparation , 763 procedure A C C . See Adrenocortical cancer anococcygeal ligament , (ACC) 441, 442 Achalasia . See Esophageal anterior dissection plane , achalasia 442, 444 Adjustable gastric banding elliptical incision , 441 (AGB) , 237, 244–245 perineal incision , 442, 445 Adrenalectomy robotic , 445–446 indications for , 62 Abscess drainage laparoscopic (see anesthesia , 761–762 (Laparoscopic antibiotic therapy , 759 adrenalectomy) ) complications , 766 open (see (Open indications , 760 adrenalectomy) ) patient positioning , 761 Adrenal incidentaloma , 63 post-procedure Adrenocortical cancer (ACC) instructions , 766 laparoscopic adrenalectomy pre-procedure evaluation , (see (Laparoscopic 760–761 adrenalectomy) ) procedure open adrenalectomy (see abscess cavity, loculations (Open of , 764, 765 adrenalectomy) ) H. Chen (ed.), Illustrative Handbook of General Surgery, 793 DOI 10.1007/978-3-319-24557-7, © Springer International Publishing Switzerland 2016 794 Index A G B . See Adjustable gastric Antirefl ux procedure (ARP) , 194 banding (AGB) Dor fundoplication Aldosterone producing advantages of , 200 adenoma , 71 completion of , 201–202 American College of creation of , 200–201 Radiologists -
Analysis of the Sinusoidal Endothelial Cell Organization During The
CELL STRUCTURE AND FUNCTION 23: 341-348 (1998) © 1998 by Japan Society for Cell Biology Analysis of the Sinusoidal Endothelial Cell Organization during the Develop- mental Stage of the Fetal Rat Liver Using a Sinusoidal Endothelial Cell Specific Antibody, SE-1 Mamoru Morita1, Wang Qun2, Hitoshi Watanabe1, Yuko Doi1, Michio Mori3, and Katsuhiko Enomoto1'* department of Pathology, Akita University School of Medicine, Hondo, Akita 010-8543, Japan, depart- ment of Pathology, School of Basic Medicine, NormanBethune University of Medical Science, Jilin, P.R. of China, and *Department of Pathology, Sapporo Medical University School of Medicine, S-l, W-17, Chuo-ku, Sapporo 060, Japan Keywords: sinusoidal endothelial cells/SE-1 antibody/fetal rat liver ABSTRACT.The sinusoid organization during the development of fetal rat livers was studied using a SE-1 antibody, which we have previously established as a specific monoclonal antibody against rat sinusoidal endo- thelial cell (SEC). Expression and localization of the SE-1 antigen in the liver tissues of 13- to 21-day-old fe- tuses were immunofluorescently and immunoelectron microscopically examined. The first positive fluorescence was observed in the immature liver of 15-day-old fetuses. The initial positive staining was randomly distrib- uted in the liver parenchyma and showed no direct relation to the large vessels which may be derived from the fetal vitelline veins. The positive linear staining increased in number and connected with each other during the course of development. The SE-1 staining pattern and the sinusoidal arrangement became similar to those of the adult liver after 20th day of gestation. Immunoelectron microscopically, the immature SEC showed a weak positive reaction for the SE-1 antigen at their membraneand was observed together with immature hepato- cytes and hematopoietic cells in the 15-day-old fetal liver. -
Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma
Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma a a,b, Lung-Yi Lee, MD , David P. Foley, MD * KEYWORDS Liver transplantation Surgery Hepatocellular carcinoma Piggyback technique Portal vein thrombosis KEY POINTS In the majority of cases, patients with cirrhosis and hepatocellular carcinoma (HCC) who undergo liver transplantation are transplanted based on their higher Model for End-Stage Liver Disease (MELD) exception score and not their physiologic MELD score; this usually results in fewer physiologic derangements during liver transplantation. Patients who have previously undergone locoregional therapy or liver resection for HCC can develop significant perihepatic adhesions that increase the complexity of the hepa- tectomy during transplant. Implantation strategy of the inferior vena cava (IVC) during liver transplant may need to be modified based on location of previously treated HCC. Patients who undergo transarterial chemoembolization for pretransplant HCC therapy may have higher rates of hepatic artery thrombosis after liver transplant; therefore, aorto- hepatic bypass grafting with donor iliac artery may be required for arterial in flow to the liver allograft. Patients with portal vein (PV) thrombosis with a bland thrombus and a patent superior mesenteric vein (SMV) can undergo successful liver transplant through either PV throm- bectomy and standard end-to-end PV-PV anastomosis, or the use of SMV-PV bypass graft with donor iliac vein. a Department of Surgery, University of Wisconsin School of Medicine and Public Health, Clinical Sciences Center, H4/766, 600 Highland Avenue, Madison, WI 53792-3284, USA; b Veterans Administration Surgical Services, William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA * Corresponding author. -
Title of My Thesis
Development of an in vitro 3D Printed Liver Sinusoid Model Soumya Sethi A Dissertation Submitted to Indian Institute of Technology Hyderabad In Partial Fulfillment of the Requirements for The Degree of Master of Technology Department of Biomedical Engineering June, 2018 Declaration I declare that this written submission represents my ideas in my own words, and where others’ ideas or words have been included, I have adequately cited and referenced the original sources. I also declare that I have adhered to all principles of academic honesty and integrity and have not misrepresented or fabricated or falsified any idea/data/fact/source in my submission. I understand that any violation of the above will be a cause for disciplinary action by the Institute and can also evoke penal action from the sources that have thus not been properly cited, or from whom proper permission has not been taken when needed. (Signature) Soumya Sethi BM16MTECH11007 (Roll No) ii Approval Sheet iii Acknowledgements I would like to thank my thesis supervisor Dr Falguni Pati for his continuous guidance. I would also like to thank my lab members especially Shibu Chameettachal, Shyama Sasikumar, Sriya for supporting me and helping me out whenever required. They have been a continuous source of inspiration for me, without their passionate participation and inputs, the project could not have been successfully conducted. iv Abstract Liver is one of the most remarkable organs of the human body as it performs various vital functions namely metabolism of fats and carbohydrates, drugs, detoxification, production of bile and has a capacity to regenerate. The intricate functional units of the liver called the sinusoids are of immense interest as they are early targets of many drugs and toxicants as well as have been reported to play a significant role in initiating liver regeneration and contribute to the pathophysiology of many liver diseases. -
Icd-9-Cm (2010)
ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular -
Dorsal Approach with Glissonian Approach for Laparoscopic Right
Wang et al. BMC Gastroenterol (2021) 21:138 https://doi.org/10.1186/s12876-021-01726-4 TECHNICAL ADVANCE Open Access Dorsal approach with Glissonian approach for laparoscopic right anatomic liver resections Shaohe Wang1,2, Yang Yue1, Wenjie Zhang1, Qiaoyu Liu1, Beicheng Sun1, Xitai Sun1 and Decai Yu1* Abstract Background: Laparoscopic anatomic hepatectomy (LAH) has gradually become a routine surgical procedure. How- ever, how to expose the whole hepatic vein and avoid the hepatic vein laceration is still a challenge because of the caudate lobe, particularly in right hepatectomy. We adopted a dorsal approach combined with Glissionian appraoch to perform laparoscopic right anatomic hepatectomy (LRAH). Methods: Twenty patients who underwent LRAH from January 2017 to November 2018 were retrospectively ana- lysed. Of these patients, seven patients underwent laparoscopic right hemihepatectomy (LRH group), seven patients who underwent laparoscopic right posterior hepatectomy (LRPH group), and six patients who underwent laparo- scopic hepatectomy for segment 7 (LS7 group). The paracaval portion of caudate lobe could be transected frstly through dorsal approach and the corresponding major hepatic vein could be exposed from its root to the periph- eral branches safely. Due to exposure along the major hepatic vein trunk, the remaining liver parenchyma could be quickly transected from dorsal to cranial side. Results: The mean age of the patients was 53.8 years and the male: female ratio was 8:12. The median operation time was 306.0 58.2 min and the mean estimated volume of blood loss was 412.5 255.4 mL. The mean duration of postoperative± hospital stay was 10.2 days. -
Small Bowel Multivisceral Transplantation MCG-117
Subject: Small Bowel Transplantation, Small Bowel and Liver Original Effective Date: Transplantation and Multivisceral Transplantation 8/30/12 Policy Number: MCP -117 Revision Date(s): 5/26 /15 Review Date: 12/16/15, 12/14/16, 6/22/17, 9/13/18 , 9/18/ 19 MCPC Approval Date: 6/22/17 , 9/13/18 , 9/18/19 DISCLAIMER This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members. -
Elimination Pathways of Nanoparticles † ‡ † ‡ ◆ † ‡ § ◆ † ‡ † ‡ Wilson Poon, , Yi-Nan Zhang, , , Ben Ouyang, , , , Benjamin R
Article Cite This: ACS Nano 2019, 13, 5785−5798 www.acsnano.org Elimination Pathways of Nanoparticles † ‡ † ‡ ◆ † ‡ § ◆ † ‡ † ‡ Wilson Poon, , Yi-Nan Zhang, , , Ben Ouyang, , , , Benjamin R. Kingston, , Jamie L. Y. Wu, , ∥ ⊥ † ‡ # ∇ ○ Stefan Wilhelm, , and Warren C. W. Chan*, , , , , † Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada ‡ Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario M5S 3E1, Canada § MD/PhD Program, Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada ∥ Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, United States ⊥ Stephenson Cancer Center, Oklahoma City, Oklahoma 73104, United States # Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario M5S 3E5, Canada ∇ Department of Materials Science and Engineering, University of Toronto, Toronto, Ontario M5S 1A1, Canada ○ Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada *S Supporting Information ABSTRACT: Understanding how nanoparticles are eliminated from the body is required for their successful clinical translation. Many promising nanoparticle formulations for in vivo medical applications are large (>5.5 nm) and nonbiodegradable, so they cannot be eliminated renally. A proposed pathway for these nanoparticles is hepatobiliary from https://pubs.acs.org/doi/10.1021/acsnano.9b01383. elimination, but their transport has